Abstract |
We reported previously the development of SMFv-PE38KDEL type I mutant (PE38KDEL-I; Mut-I), a recombinant immunotoxin in which a single-chain antibody derived from mouse SM5-1 monoclonal antibody is genetically fused to PE38KDEL-I. In comparison with the SMFv-PE38KDEL wild-type, Mut-I showed improved therapeutic efficacy and reduced toxicity. To overcome the problems associated with the immune response to the Pseudomonas exotoxin A (PE) component of Mut-I, we have constructed PE38KDEL-I-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with F(ab') fragments of a humanized SM5-1 monoclonal antibody (PE-NP-S). PE-NP-S specifically bound to SM5-1 binding protein-expressing hepatocellular carcinoma cell lines and was then internalized by these cells, resulting in significant cytotoxic effect. In SM5-1 binding protein-overexpressing tumor xenograft model, administration of PE-NP-S significantly inhibited tumor development and induced tumor regression. Moreover, PE-NP-S was shown to be much weaker in inducing vascular leakage syndrome in mice than Mut-I. The LD(50) of PE-NP-S was about 4-fold higher than that of Mut-I. Remarkably, PE-NP-S was of low immunogenicity in development of anti-PE neutralizing antibodies in vivo and was less susceptible to inactivation by anti-PE neutralizing antibodies compared with Mut-I. In conclusion, the resultant PE-NP-S possessed increased cancer therapeutic efficacy and had reduced nonspecific toxicity and immunogenicity, suggesting that it is a potential candidate in cancer therapy.
|
Authors | Jie Gao, Geng Kou, Huaiwen Chen, Hao Wang, Bohua Li, Ying Lu, Dapeng Zhang, Shuhui Wang, Sheng Hou, Weizhu Qian, Jianxin Dai, Jian Zhao, Yanqiang Zhong, Yajun Guo |
Journal | Molecular cancer therapeutics
(Mol Cancer Ther)
Vol. 7
Issue 10
Pg. 3399-407
(Oct 2008)
ISSN: 1535-7163 [Print] United States |
PMID | 18852143
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
- Immunotoxins
- Polylactic Acid-Polyglycolic Acid Copolymer
- Polyglycolic Acid
- Lactic Acid
|
Topics |
- Animals
- Antibodies
- Antibodies, Monoclonal
(therapeutic use)
- Binding, Competitive
(drug effects)
- Carcinoma, Hepatocellular
(drug therapy)
- Cell Proliferation
(drug effects)
- Endocytosis
(drug effects)
- Humans
- Immunoglobulin Fab Fragments
(therapeutic use, toxicity)
- Immunotoxins
(therapeutic use, toxicity)
- Lactic Acid
(metabolism)
- Liver Neoplasms
(drug therapy)
- Mice
- Microscopy, Confocal
- Nanoparticles
- Polyglycolic Acid
(metabolism)
- Polylactic Acid-Polyglycolic Acid Copolymer
- Xenograft Model Antitumor Assays
|